deltatrials
Suspended PHASE2 INTERVENTIONAL 4-arm NCT04166552

Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis

A Phase IIa, Double-Blind, Randomised, Intracohort Placebo-Controlled, Multicentre Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101 in Patients With Diffuse Cutaneous Systemic Sclerosis

Sponsor: Emerald Health Pharmaceuticals

Conditions Diffuse Cutaneous Systemic Sclerosis
Interventions Patients will be randomized to receive EHP-101 or Placebo
Updated 18 times since 2019 Last updated: Sep 16, 2023 Started: Jun 11, 2020 Primary completion: Jul 31, 2024 Completion: Oct 31, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Suspended

Sponsor ceasing all operations due to company's shut down

Listed as NCT04166552, this PHASE2 trial focuses on Diffuse Cutaneous Systemic Sclerosis and remains suspended. Sponsored by Emerald Health Pharmaceuticals, it has been updated 18 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Aug 2020 · 6 months · monthly snapshot~Aug 2020 – ~Nov 2020 · 3 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Jun 2021 · 4 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Feb 2022 · 3 months · monthly snapshot~Feb 2022 – ~May 2022 · 3 months · monthly snapshot~May 2022 – ~Jul 2022 · 2 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Oct 2023 · 13 months · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2024 — Present [monthly]

    Suspended PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Suspended PHASE2

  3. Oct 2023 — Jul 2024 [monthly]

    Suspended PHASE2

    Status: Recruiting → Suspended

  4. Sep 2022 — Oct 2023 [monthly]

    Recruiting PHASE2

  5. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

▶ Show 13 earlier versions

  1. May 2022 — Jul 2022 [monthly]

    Recruiting PHASE2

  2. Feb 2022 — May 2022 [monthly]

    Recruiting PHASE2

  3. Nov 2021 — Feb 2022 [monthly]

    Recruiting PHASE2

  4. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

  5. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE2

  6. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  7. Feb 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  8. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  9. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  10. Aug 2020 — Nov 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  11. Feb 2020 — Aug 2020 [monthly]

    Not Yet Recruiting PHASE2

  12. Jan 2020 — Feb 2020 [monthly]

    Not Yet Recruiting PHASE2

  13. Dec 2019 — Jan 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Emerald Health Pharmaceuticals
Data source: Emerald Health Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Altamonte Springs, United States , Caguas, Puerto Rico , Camperdown, Australia , Chicago, United States , Cleveland, United States , Footscray, Australia , Gold Coast, Australia , Huntington Beach, United States , Los Angeles, United States and 11 more locations